Trials / Completed
CompletedNCT02445352
Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R207 (Rosuvastatin /Ezetimibe Combination) and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 379 (actual)
- Sponsor
- Alvogen Korea · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate efficacy and safety of DP-R207 in patients with primary hypercholesterolemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosuvastatin 5mg | |
| DRUG | DP-R207 5/10mg | |
| DRUG | Rosuvastatin 10mg | |
| DRUG | DP-R207 10/10mg | |
| DRUG | Rosuvastatin 20mg | |
| DRUG | DP-R207 20/10mg | |
| DRUG | Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg) | |
| DRUG | Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg) | |
| DRUG | Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg) |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2015-01-01
- Completion
- 2015-03-01
- First posted
- 2015-05-15
- Last updated
- 2015-05-15
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02445352. Inclusion in this directory is not an endorsement.